Renalytix AI PLC Conference attendance (9355D)
25 Febbraio 2020 - 08:00AM
UK Regulatory
TIDMRENX
RNS Number : 9355D
Renalytix AI PLC
25 February 2020
Renalytix AI plc
("RenalytixAI", the "Company" or the "Group")
Conference attendance
CEO speaking at Cowen 40th Annual Health Care Conference
Renalytix AI plc (LSE : RENX), a developer of artificial
intelligence enabled clinical diagnostics for kidney disease,
announces it will be presenting at the Cowen 40th Annual Health
Care Conference, which runs from the 1-4 March 2020, hosted at
Boston Marriott Copley Place, Boston, USA.
The conference brings together top institutional investors and
leading companies operating in the Health Care space.
James McCullough, CEO of Renalytix, will be presenting on
Tuesday 3 March at 8.40am - 9.10am in Simmons, 3(rd) Floor.
The presentation will be made available on the Company's website
shortly after here:
https://renalytixai.com/investors/company-presentation/ and no
new material or trading information will be provided.
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker) Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker) Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
About Kidney Disease
Kidney disease is now recognised as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control estimates there that 15% of United States adults or 37
million people currently have chronic kidney disease. It is
reported that 9 out of 10 adults with CKD do not know they have it
and 1 out of 2 people with very low kidney function who are not on
dialysis do not know they have CKD*. Kidney disease is referred to
as a "silent killer" because it often has no symptoms and can go
undetected until a very advanced stage. Each year kidney disease
kills more people than breast and prostate cancer. Every day 13
patients die in the United States while waiting for a kidney
transplant.
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled
clinical in vitro diagnostic solutions for kidney disease, one of
the most common and costly chronic medical conditions globally. The
Company's products are being designed to make significant
improvements in kidney disease diagnosis, transplant management,
clinical care, patient stratification for drug clinical trials, and
drug target discovery.
For more information, visit renalytixai.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADZGZZFDDGGZM
(END) Dow Jones Newswires
February 25, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Renalytix (LSE:RENX)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Renalytix (LSE:RENX)
Storico
Da Mar 2023 a Mar 2024